|

Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma

RECRUITINGSponsored by University Hospital, Strasbourg, France
Actively Recruiting
SponsorUniversity Hospital, Strasbourg, France
Started2025-04-20
Est. completion2026-04
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07339878

Summary

The standard first-line treatment for metastatic urothelial carcinoma has become the combination of Enfortumab Vedotin and Pembrolizumab following the publication of the EV-302 study results at the end of 2024. Another standard remains in 2025 for patients who are not eligible for the EV Pembrolizumab combination, namely platinum-based chemotherapy +/- avelumab in cases of non-progression. The objective of the FLORAL study is to determine the characteristics of these patients and the reasons that led clinicians to prefer a first-line treatment based on platinum salts.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients over 18 years of age
* Metastatic urothelial carcinoma
* Treated with first-line metastatic therapy since October 2024

Exclusion Criteria:

* Patient who expressed opposition to participating in the study

Conditions2

CancerMetastatic Urothelial Carcinoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.